Follow Us
Follow Us
Follow Us

Sphenopalatine Ganglion Block for the Treatment of Headache and Facial Pain

Below is the abstract of the study A Novel Revision to the Classical Transnasal Tropical Sphenopalatine Ganglion Block Treatment of Headache and Facial Pain the study addresses the use of the Tx360® Nasal Applicator and it's effectiveness in clinical testing. This study has been printed by the Pain Physicians Journal: Offical Journal of the American Society of Interventional Pain Physicians.

The study concludes that the relief experienced by patients from the techniques used by the MiRx Protocol significantly reduces migraine and head pain. Also the ease of the Tx360® proved to be an excellent method of application for pain specialists, the board also concluded that the they believe the Tx360® could be used in the busiest of primary care and emergency department settings. The SPG block with the Tx360® provides for a fast, inexpensive, easy-to-use intervention in a variety of environments.

To read the full study Click Here.

 November/December 2013 – Vol 1 Issue 6

ABSTRACT

2013;16;E769-E778. A Novel Revision to the Classical Transnasal Topical Sphenopalatine Ganglion Block for the Treatment of Headache and Facial Pain

Case Series

Kenneth D. Candido, MD, Scott T Massey, MD, Ruben Sauer, MD, Raheleh Rahimi Darabad, MD, and Nebojsa Nick Knezevic, MD, PhD

BACKGROUND

The sphenopalatine ganglion (SPG) is located with some degree of variability near the tail or posterior aspect of the middle nasal turbinate. The SPG has been implicated as a strategic target in the treatment of various headache and facial pain conditions, some of which are featured in this manuscript. Interventions for blocking the SPG range from minimally to highly invasive procedures often associated with great cost and unfavorable risk profiles.

OBJECTIVE: The purpose of this pilot study was to present a novel, FDA-cleared medication delivery device, the Tx360® nasal applicator, incorporating a transnasal needleless topical approach for SPG blocks. This study features the technical aspects of this new device and presents some limited clinical experience observed in a small series of head and face pain cases.

STUDY DESIGN: Case series.

SETTINGS: Pain management center, part of teaching-community hospital, major metropolitan city, United States.

METHODS: After Institutional Review Board (IRB) approval, the technical aspects of this technique were examined on 3 patients presenting with various head and face pain conditions including trigeminal neuralgia (TN), chronic migraine headache (CM), and post-herpetic neuralgia (PHN).

The subsequent response to treatment and quality of life was quantified using the following tools: the 11-point Numeric Rating Scale (NRS), Modified Brief Pain Inventory — short form (MBPI-sf), Patient Global Impression of Change (PGIC), and patient satisfaction surveys. The Tx360® nasal applicator was used to deliver 0.5 mL of ropivacaine 0.5% and 2 mg of dexamethasone for SPG block. Post-procedural assessments were repeated at 15 and 30 minutes, and on days one, 7, 14, and 21 with a final assessment at 28 days post-treatment. All patients were followed for one year. Individual patients received up to 10 SPG blocks, as clinically indicated, after the initial 28 days.

RESULTS: Three women, ages 43, 18, and 15, presented with a variety of headache and face pain disorders including TN, CM, and PHN. All patients reported significant pain relief within the first 15 minutes post-treatment. A high degree of pain relief was sustained throughout the 28 day follow-up period for 2 of the 3 study participants. All 3 patients reported a high degree of satisfaction with this procedure. One patient developed minimal bleeding from the nose immediately post-treatment which resolved spontaneously in less than 5 minutes. Longer term follow-up (up to one year) demonstrated that additional SPG blocks over time provided a higher degree and longer lasting pain relief.

LIMITATIONS: Controlled double blind studies with a higher number of patients are needed to prove efficacy of this minimally invasive technique for SPG block.

CONCLUSION: SPG block with the Tx360® is a rapid, safe, easy, and reliable technique to accurately deliver topical transnasal analgesics to the area of mucosa associated with the SPG. This intervention can be delivered in as little as 10 seconds with the novice provider developing proficiency very quickly. Further investigation is certainly warranted related to technique efficacy, especially studies comparing efficacy of Tx360 and standard cotton swab techniques.

To read the full study Click Here.

 

A Double-Blind, Placebo-Controlled Study of Repetitive Transnasal Sphenopalatine Ganglion Blockade With Tx360® as Acute Treatment for Chronic Migraine

The study below A Double-Blind, Placebo-Controlled Study of Repetitive Transnasal Sphenopalatine Ganglion BlockadeWith Tx360®as Acute Treatment for Chronic Migraine addresses the use of the Tx360® Nasal Applicator and it's effectiveness in clinical testing. 

Read the full article Click Here.

October 23, 2014

ABSTRACT 

Objective

To determine if repetitive sphenopalatine ganglion (SPG) blocks with 0.5% bupivacaine delivered through the Tx360® are superior in reducing pain associated with chronic migraine (CM) compared with saline.

Background

The SPG is a small concentrated structure of neuronal tissue that resides within the pterygopalatine fossa (PPF) in close proximity to the sphenopalatine foramen and is innervated by the maxillary division of the trigeminal nerve. From an anatomical and physiological perspective, SPG blockade may be an effective acute and preventative treatment for CM.

Method

This was a double-blind, parallel-arm, placebo-controlled, randomized pilot study using a novel intervention for acute treatment in CM. Up to 41 subjects could be enrolled at 2 headache specialty clinics in the US. Eligible subjects were between 18 and 80 years of age and had a history of CM defined by the second edition of the International Classification of Headache Disorders appendix definition. They were allowed a stable dose of migraine preventive medications that was maintained throughout the study. Following a 28-day baseline period, subjects were randomized by computer-generated lists of 2:1 to receive 0.5% bupivacaine or saline, respectively. The primary end-point was to compare numeric rating scale scores at pretreatment baseline vs 15 minutes, 30 minutes, and 24 hours postprocedure for all 12 treatments.

SPG blockade was accomplished with the Tx360®, which allows a small flexible soft plastic tube that is advanced below the middle turbinate just past the pterygopalatine fossa into the intranasal space. A 0.3 cc of anesthetic or saline was injected into the mucosa covering the SPG. The procedure is performed similarly in each nostril. The active phase of the study consisted of a series of 12 SPG blocks with 0.3 cc of 0.5% bupivacaine or saline provided 2 times per week for 6 weeks. Subjects were re-evaluated at 1 and 6 months postfinal procedure.

Results

The final dataset included 38 subjects, 26 in the bupivacaine group and 12 in the saline group. A repeated measures analysis of variance showed that subjects receiving treatment with bupivacaine experienced a significant reduction in the numeric rating scale scores compared with those receiving saline at baseline (M = 3.78 vs M = 3.18, P = .10), 15 minutes (M = 3.51 vs M = 2.53, P < .001), 30 minutes (M = 3.45 vs M = 2.41, P < .001), and 24 hours after treatment (M = 4.20 vs M = 2.85, P < .001), respectively. Headache Impact Test-6 scores were statistically significantly decreased in subjects receiving treatments with bupivacaine from before treatment to the final treatment (Mdiff = −4.52, P = .005), whereas no significant change was seen in the saline group (Mdiff = −1.50, P = .13).

Conclusion

SPG blockade with bupivacaine delivered repetitively for 6 weeks with the Tx360® device demonstrates promise as an acute treatment of headache in some subjects with CM. Statistically significant headache relief is noted at 15 and 30 minutes and sustained at 24 hours for SPG blockade with bupivacaine vs saline. The Tx360® device was simple to use and not associated with any significant or lasting adverse events. Further research on sphenopalatine ganglion blockade is warranted.

References

Cady, R., Saper, J., Dexter, K. and Manley, H. R. (2014), A Double-Blind, Placebo-Controlled Study of Repetitive Transnasal Sphenopalatine Ganglion Blockade With Tx360® as Acute Treatment for Chronic Migraine. Headache: The Journal of Head and Face Pain. doi: 10.1111/head.12458

Sphenopalatine Ganglion Nerve Block Studies & Resources

Recently the Tx360 has been the center of pilot studies to evaluate the effectiveness of its method to administer a nerve block of the sphenopalatine ganglion nerve (SPG).  The study below is of the Tx360 device and technology.  

The study concludes that the relief experienced by patients from the techniques used by the MiRx Protocol significantly reduces migraine and head pain.   

Tx360TM a Minimally-Invasive Technique for Sphenopalatine Ganglion Nerve Block in the treatment of head and face pain: a case series.


Kenneth D. Candido, MD; N. Nick Knezevic, MD, PhD.; Ruben I. Sauer, Lalida Chupatanakul, MD.
Department of Anesthesiology, Advocate Illinois Masonic Medical Center, University of Illinois, Chicago, IL.

Abstract

The Sphenopalatine ganglion (SPG) is located on the posterior aspect of the middle nasal turbinate and has been implicated as a strategic target in the treatment of various head and face pain conditions. 

The purpose of this pilot study was to evaluate the effect of the novel, revised method for SPG nerve block with the use of the Tx360.

We are presenting three patients with various head and face pain conditions (post-herpetic neuralgia, chronic migraine, and trigeminal neuralgia).  The average baseline NRS pain score was 7.  All patients reported significant pain relief within the first 15 minutes post-treatment with an average NRS score of 2.  High degree of pain relief was sustained throughout the 28 day follow-up period for 2 of the 3 study participants.  

Introduction/Methods

  • The literature is rich with different examples of SPG interventions for painful face and head conditions.
  • These interventions range from significantly invasive to non-invasive and from cumbersome, technical, and expensive to fast, simple and inexpensive.
  • Regardless of the approach, the intent of the SPG intervention is to block or modulate its function thereby eliminating head pain.
  • This effect can either be temporary of permanent depending on the technique.
  • The transnasal approach is the simplest safest, and least expensive of the SPG interventions.  With this technique, a topical anesthetic blocking agent can be delivered to the area of mucosa associated with the SPG.
  • The Tx360 overcomes inaccuracy and patient discomfort associated with the long-standing cotton-tip application of transnasal technique.
  • In addition, it can be used with deviated septum patients unlike its predecessor.
  • After IRB approval three subjects were included, and followed for 28 days with NRS pain score, patient's global impression of change (PGIC) and Modified Brief Pain Inventory Short form )MBPI-sf), satisfaction and use of pain medications.

Results

 

Sphenopalatine Ganglion (SPG) Studies & Resources

Paitent #1 (Blue)

  • A 15-year-old female with two year history of bilateral supraorbital headaches due to postherpetic neuralgia, and post-decompression of Arnold Chiari malformation.
  • Pharmacotherapy was attempted for 12 months with no improvements in her symptoms.
  • Initial pain level prior to treatment was 9/10 
  • Result was a drop to 5/10 in 15 minutes sustained for nearly 20 minutes.  Repeated treatments made more significant pain relief at day 14 the experience was 3/10 on the NRS.

Patient #2 (Red)

  • 18 year-old female with refractory migraines secondary to a fall in 2010.  The patient fell on her left head/neck/shoulder area.  10 days later, she started experiencing migraines with the most intense pain being on the left infraorbital region and right supraorbital region.
  • Infraorbital and supraorbital nerve blocks were administered. Pharmacotherapy offered marginal temporary pain relief down to a level of 5/10 on the NRS pain scale.  The patient had significant improvement during the first two weeks after SPG block. 
  • After the treatment the pain dropped to 1/10 (NRS) and sustained at or below a 1 for 14 days.

Patient #3 (Green)

  • 43-year-old woman presented with daily, paroxysmal, sharp, shooting pain and numbness in her left cheek for the past 18 months.
  • A dental consult resulted in a tooth extraction and root canal which did not provide pain relief.  Subsequently, the patient was diagnosed with trigeminal neuralgia.  Pre-procedure pain level was 8/10 (NRS).
  • After the treatment with the Tx360 and sphenopalatine nerve block the pain dropped to 1/10 in 15 minutes, and sustained at or below a 1 for nearly 7 days.

Conclusions 

  • SPGB with Tx360TM provides rapid clinically significant pain relief with minimal complications at a very low cost.
  • As the maximal levels of pain relief were observed to diminish a couple of weeks post-treatment, the efficacy of serial interventions should be investigated.
  • Additional studies are needed to assess the efficacy of this technique across the entire spectrum of head and face pain conditions.
  • The ease of the Tx360TM should allow for broad potential use beyond the pain specialist, even in the busiest primary care and ER departments.

 

References

  1. PiagkuM, et al. The Pterygopalatine Ganglion and its Role in Various Pain Syndromes: From Anatomy to Clinical Practice. Pain Pract. 2011;29:1-4
  2. Yarnitsky D, et al. 2003 Wolff Award: Possible parasympathetic contributions to peripheral and central sensitization during migraine. Headache 2003;43:  704-14
  3. Maizels M, et al. Intranasal lidocane for migrane:  A randomized trial and open-label follow-up. Headache 1999;39: 543-51

 

 

Additional SPG Nerve Block Resources: 

 

1.) Rapid and sustained relief of migraine attacks with intranasal lidocaine: preliminary findings.
Headache. 1995 Feb;35(2):79-82. Kudrow L, Kudrow DB, Sandweiss JH.
California Medical Clinic for Headache, Encino 91436, USA.

http://www.ncbi.nlm.nih.gov/pubmed/7737865

2.) Intranasal Lidocaine for Treatment of MigraineA Randomized, Double-blind, Controlled Trial
Morris Maizels, MD; Barbara Scott; Wendy Cohen, MD; Wansu Chen, MS
JAMA. 1996;276(4):319-321. doi:10.1001/jama.1996.03540040063034.

http://jama.jamanetwork.com/article.aspx?articleid=405844

3.) Sphenopalatine ganglion block: a safe and easy method for the management of orofacial pain.
Peterson JN, Schames J, Schames M, King E.
Source: Headache and Pain Center, Hollywood Community Hospital, Los Angeles, CA 90028, USA.
Cranio. 1995 Jul;13(3):177-81.

http://www.ncbi.nlm.nih.gov/pubmed/8949858

4.) Over 3 Million Look to Hospitals for Headache Relief, Particularly for Migraines
AHRQ News and Numbers, May 4, 2011

http://www.ahrq.gov/news/newsroom/news-and-numbers/050411.html

5.) A new interest in an old remedy for headache and backache for our obstetric patients: a sphenopalatine ganglion block
S. Cohen, S. Trnovski, Y. Zada Article first published online: 26 JUL 2007
DOI: 10.1111/j.1365-2044.2001.2094-34.x

http://onlinelibrary.wiley.com/doi/10.1111/j.1365-2044.2001.2094-34.x/full

6.) Intranasal lidocaine 8% spray for second-division trigeminal neuralgia
A. Kanai*, A. Suzuki, M. Kobayashi and S. Hoka
- Author Affiliations - Department of Anesthesiology, Kitasato University School of Medicine1-15-1. Kitasato, Sagamihara 228-8555, Japan

http://bja.oxfordjournals.org/content/97/4/559

Tx360® Studies & Resources

The first study A Double-Blind, Placebo-Controlled Study of Repetitive Transnasal Sphenopalatine Ganglion Blockade With Tx360® as Acute Treatment for Chronic Migraine addresses the use of the Tx360® Nasal Applicator and it's effectiveness in clinical testing. The article is from the Headache: The Journal of Head and Face Pain. 

Read the abstract Click Here.

The second study A Novel Revision to the Classical Transnasal Tropical Sphenopalatine Ganglion Block Treatment of Headache and Facial Pain the study addresses the use of the Tx360® Nasal Applicator and it's effectiveness in clinical testing. This study has been printed by the Pain Physicians Journal: Offical Journal of the American Society of Interventional Pain Physicians.

The study concludes that the relief experienced by patients from the techniques used by the MiRx Protocol significantly reduces migraine and head pain. Also the ease of the Tx360® proved to be an excellent method of application for pain specialists, the board also concluded that the they believe the Tx360® could be used in the busiest of primary care and emergency department settings. The SPG block with the Tx360® provides for a fast, inexpensive, easy-to-use intervention in a variety of environments.

To read abstract Click Here.

 

 

 

 

Physical Therapy for Migraine Triggers

Physical Component:

Bio-Mechanical Therapy can be used to get rid of headaches.

For most MiRx patients headache relief is instantaneous and the medical component can reduce the painful sensation by 90%, however that is only one aspect of the protocol.  Long-term headache pain relief is acheived with the bio-mechanical or physical component of the protocol.  This focuses on bio-feedback (lab work & diagnosic tests), and patient observations to identify the triggers that are the root cause of their chronic headaches.  

The goal of the physical component is to help the body control reactions to physical, environmental, and psychological triggers.  If these are not addressed and rehabilitated then long term pain relief is difficult achieve.  

Physiological treatments often includes:

  • Physical Therapy - Reduce tension and balance the body.  
  • Ergonomic Modifictations - Doctors will recommend a changes to work environment that will reduce physical triggers
  • Dietary - Diagnostic testing identifies food intollerances and sensitivities that can compound chronic headaches
  • Weight Loss - Managing a healthy weight can reduce tension headaches and improve associated triggers
  • Chemical Imbalance - Monitoring and managing hormone fluctuations
  • Cranialsacral therapy -  Specialized head massage techniqe that focuses on the bones of the skull
  • Massage Therapy -  Incredibly helpful when treating tension headaches

 

The focus and goal of the MiRx Protocol is to provide a long term resolution for chronic headache suffers. By addressing the physical factors that contribute to chronic headaches the paitents can continue to experience relief for long durations.  Some will never experience headaches again.  There are not specific cures for headaches but the Mirx Protocol provides an effective combination of medical intervention and bio mechanical rehabilitation.  

 

MiRx™ TREATMENT

 

 

MiRx™ TESTIMONIALS

 

 

FIND A DOCTOR
NEAR YOU

FREE eBOOK DOWNLOAD

Living with Headaches:
Solutions that Work

The MiRx™ Protocol is made up of two parts that first stops the reaction of the nervous system, the medical component; then treats and rehabilitates.

The MiRx™ Protocol is made up of two parts that first stops the reaction of the nervous system, the medical component; then treats and rehabilitates.

DOWNLOAD NOW